Peptide Therapeutics Market: Global Industry Analysis, Trends, Market Size & Forecasts to 2023

  • ID: 4397164
  • Report
  • Region: Global
  • 120 pages
  • Infinium Global Research
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bachem Holding AG
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
The report on global Peptide Therapeutics market provides qualitative and quantitative analysis for the period of 2017 to 2023. The report predicts the global Peptide Therapeutics market to grow with a CAGR between 9.0% and 9.5 % from 2017 to 2023. The global Peptide Therapeutics market was worth USD 21.12 Billion in 2016.The study on Peptide Therapeutics market covers the analysis of regions such as North America, Europe, Asia Pacific, and Rest of the World. Among the geographies North America dominated the world market and Asia Pacific anticipated growing at the highest CAGR over the forecast period.

The report on global Peptide Therapeutics market is a comprehensive study of demand, market size, forecasts, trends and factors affecting the global Peptide Therapeutics market. Moreover, the report is collective presentation of primary and secondary research findings. In addition, it provides deep insights on the factors that driving, restraining the global Peptide Therapeutics market. Porter’s five forces model in the report provides insights into the competitive rivalry in the global Peptide Therapeutics market over the period of 2017-2023. Further, the Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Research Methodology

Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through:

1. Key Opinion Leaders associated with the author
2. Internal and External subject matter experts
3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers

Primary research respondents typically include:
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:
  • Company reports and publications
  • Government/institutional publications
  • Trade and associations’ journals
  • Databases such as WTO, OECD, and Worldbank, among others.
  • Websites and publications by research agencies
Report Findings

1. Drivers
  • Increasing prevalence of metabolic disorder with increasing pool of cancer patient.
  • Recent technological advancement in peptide therapies.
2. Restraints
  • Complexity of peptide therapies resulted in reduction of manufacturing of peptide drugs.
3. Opportunities
  • Increasing cancer population across the globe.
  • Technological reforms in peptide therapeutics
Segments Covered

1. Global Peptide Therapeutics market

a. By drug class
  • Luteinizing hormone (LH)-releasing hormone (LHRH)
  • Somatostatins
  • Glucagon and analogs
  • Insulins
  • Vasopressin
  • Calcitonins
  • Other
b. By Route of administration
  • Oral
  • Parental
  • Others
c. By technology
  • Liquid Phase
  • Solid Phase
  • Hybrid Phase
2. Global Peptide Therapeutics market by Region
a. North America
b. Europe
c. Asia Pacific
d. Row

Companies Profiled:
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co. Ltd
  • GlaxoSmithKline Plc
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bachem Holding AG
  • Amgen Inc
Reasons to buy this report

1. Comprehensive analysis of global as well as regional markets of Peptide Therapeutics.
2. Complete coverage of all the product type and applications segments to analyze the trends, developments in Peptide Therapeutics market, and forecast of market size up to 2023.
3. Comprehensive analysis of the companies operating in Peptide Therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. The author's Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bachem Holding AG
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
1. Preface
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches

2. Executive Summary

3. Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.2.4 Challenges
3.3 Porter’s Five Forces Analysis
3.4 Growth Matrix Analysis
3.5 Competitive Landscape in the Peptide Therapeutics Market

4. Global Peptide Therapeutics Market: Snapshots
4.1 Global Peptide Therapeutics Market key trends
4.2 Global Peptide Therapeutics Market by Drug type
4.3 Global Peptide Therapeutics Market by Route of administration
4.4 Global Peptide Therapeutics Market by technology
4.5 Global Peptide Therapeutics Market by Region

5. Global Peptide Therapeutics by Drug Type (USD Billion) 2017-2023
5.1 Luteinizing hormone (LH)-releasing hormone (LHRH)
5.2 Somatostatins
5.3 Glucagon and analogs
5.4 Insulins
5.5 Vasopressin
5.6 Calcitonins
5.7 Other

6. Global Peptide Therapeutics Market Analysis, by Route of administration (USD Billion) 2017-2023
6.1 Oral
6.2 Parental,
6.3 Others

7. Global Peptide Therapeutics Market Analysis, by Technology (USD Billion) 2017-2023
7.1 Liquid Phase
7.2 Solid Phase
7.3 Hybrid Phase

8. Global Peptide Therapeutics Market Analysis, by Region (USD Billion) 2017-2023
8.1 North America
8.1.1 North America Peptide Therapeutics Market by Drug Type (USD Billion
8.1.2 North America Peptide Therapeutics Market by Route of Administration(USD Billion)
8.1.3 North America Peptide Therapeutics Market by Technology Type (USD Billion)
8.2 Europe
8.2.1 Europe Peptide Therapeutics Market by Drug class(USD Billion
8.2.2 Europe Peptide Therapeutics Market by Route of Administration (USD Billion)
8.2.3 Europe Peptide Therapeutics Market by Technology Type (USD Billion)
8.3 Asia Pacific
8.3.1 Asia Pacific Peptide Therapeutics Market by Drug class (USD Billion
8.3.2 11.3.3 Asia Pacific Peptide Therapeutics Market by Route of Administration(USD Billion)
8.3.3 Asia Pacific Peptide Therapeutics Market by Technology Type (USD Billion)
8.4 RoW
8.4.1 RoW Peptide Therapeutics Market by Drug class (USD Billion
8.4.2 RoW Peptide Therapeutics Market by Route of Administration(USD Billion)
8.4.3 RoW Peptide Therapeutics Market by Technology Type (USD Billion)

9. Company Profiles
9.1 Teva Pharmaceutical Industries Ltd
9.2 Takeda Pharmaceutical Co. Ltd
9.3 GlaxoSmithKline Plc
9.4 Sanofi
9.5 Pfizer Inc
9.6 Novartis AG
9.7 F. Hoffmann-La Roche Ltd
9.8 Eli Lilly and Co
9.9 Bachem Holding AG
9.10 Amgen Inc
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co. Ltd
  • GlaxoSmithKline Plc
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bachem Holding AG
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll